Integrin/TGF-β1 inhibitors highly effective in attenuating COVID-19 severity

By | January 5, 2022
New study results suggest that integrin inhibitors have the potential to both prevent infection with SARS-CoV-2, including the Delta and Omicron variants, and to decrease TGF-β levels, resulting in a decrease in COVID-19 severity, hospitalization, and death, especially in vulnerable and unvaccinated populations.